AVXL — Anavex Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- $352.67m
- $208.91m
- 48
- 24
- 29
- 25
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 29.1 | 31.1 | 42 | 51 | 55.8 |
Operating Profit | -29.1 | -31.1 | -42 | -51 | -55.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.2 | -26.3 | -37.6 | -47.6 | -47.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -26.3 | -26.3 | -37.9 | -48 | -47.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -26.3 | -26.3 | -37.9 | -48 | -47.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.3 | -26.3 | -37.9 | -48 | -47.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.538 | -0.452 | -0.543 | -0.624 | -0.595 |